Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis
This study has been completed.
First Received: April 10, 2007   Last Updated: February 5, 2009   History of Changes
Sponsored by: Novartis
Information provided by: Novartis
ClinicalTrials.gov Identifier: NCT00459537
  Purpose

This study will evaluate the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride applied daily versus 5% amorolfine nail lacquer applied twice a week in patients with mild to moderate toenail onychomycosis, for a total treatment duration of 48 weeks.


Condition Intervention Phase
Onychomycosis
Drug: terbinafine hydrogen chloride
Drug: amorolfine nail lacquer
Phase III

MedlinePlus related topics: Molds
Drug Information available for: Chlorides Amorolfine Terbinafine hydrochloride Terbinafine Hydrochloric acid
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Open-Label, Active-Controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Efficacy assessed by complete cure rate (negative culture, negative KOH microscopy and no residual disease involvement) at the end of study (week 52) after treating patients for 48 weeks.

Secondary Outcome Measures:
  • Efficacy assessed by mycological cure (negative culture and negative KOH microscopy) and clinical efficacy (less than 10% residual disease involvement) at the end of study after treating patients for 48 weeks.
  • Safety and tolerability assessed by adverse events and laboratory values.
  • Explore patient's satisfaction with medication using a validated questionnaire.

Enrollment: 1029
Study Start Date: March 2007
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
terbinafine hydrogen chloride
Drug: terbinafine hydrogen chloride
10 % terbinafine hydrogen chloride (HCL)
2: Active Comparator
amorolfine nail lacquer
Drug: amorolfine nail lacquer
5 % amorolfine nail lacquer

  Eligibility

Ages Eligible for Study:   12 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and females 12 - 75 years of age
  • Fungal toenail infection of one or both of the large (great) toenails
  • The nail infection must be due to a dermatophyte, (mixed infections [dermatophyte and non-dermatophyte] are not allowed)
  • The target toenail area must have at least 25% to no more than 75% disease involvement without spikes.

Exclusion Criteria:

  • Target foot must not have severe plantar (moccasin) tinea pedis that would require systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be treated with terbinafine prior to baseline or at any time during the trial. Other topical treatments for athlete's foot may be recommended at the discretion of the investigator.
  • Subjects must not have abnormalities of the nail that could prevent a normal appearing nail if clearing of infection is achieved
  • No administration of systemic antifungal medications within 6 months prior to screening visit
  • No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit
  • Patients with the target toenail involving the matrix (lunula) or having less than 2mm clear (unaffected) nail plate length beyond the proximal fold.
  • Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail.
  • No professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit
  • Known pregnancy or lactation at time of enrollment

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00459537

Locations
Finland
Novartis Investigative Site
Various Cities, Finland
France
Novartis Investigative Site
Various Cities, France
Germany
Novartis Investigative Site
Various Cities, Germany
Hungary
Novartis Investigative Site
Various Cities, Hungary
Iceland
Novartis Investigative Site
Various Cities, Iceland
Norway
Novartis Investigative Site
Various Cities, Norway
Poland
Novartis Investigative Site
Various Cities, Poland
Russian Federation
Novartis Investigative Site
Various Cities, Russian Federation
Spain
Novartis Investigative Site
Various Cities, Spain
Turkey
Novartis Investigative Site
Various Cities, Turkey
Sponsors and Collaborators
Novartis
Investigators
Study Director: Novartis Novartis
  More Information

No publications provided

Responsible Party: Novartis ( External Affairs )
Study ID Numbers: CSFO327N2303
Study First Received: April 10, 2007
Last Updated: February 5, 2009
ClinicalTrials.gov Identifier: NCT00459537     History of Changes
Health Authority: Finland: National Agency for Medicines;   France: Afssaps - French Health Products Safety Agency;   Germany: Federal Institute for Drugs and Medical Devices;   Hungary: Országos Gyógyszerészeti Intézet;   Iceland: Icelandic Medicines Control Agency;   Norway: Norwegian Medicines Agency;   Poland: Central Register of Clinical Trials;   Russia: Ministry of Health and Social Development of the Russian Federation;   Spain: Ministry of Health;   Turkey: T.C. Sağlık Bakanlığı

Keywords provided by Novartis:
Toenail fungus
Onychomycosis
Nail fungus
Toenail fungal infection
Tinea unguium
Dermatophytes
Foot dermatoses

Study placed in the following topic categories:
Mycoses
Skin Diseases, Infectious
Onychomycosis
Skin Diseases
Clotrimazole
Amorolfin
Miconazole
Antifungal Agents
Tioconazole
Tinea
Terbinafine
Dermatomycoses

Additional relevant MeSH terms:
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Skin Diseases
Amorolfin
Enzyme Inhibitors
Infection
Pharmacologic Actions
Mycoses
Skin Diseases, Infectious
Onychomycosis
Nail Diseases
Antifungal Agents
Therapeutic Uses
Tinea
Dermatomycoses
Terbinafine

ClinicalTrials.gov processed this record on May 07, 2009